Figure 1. Cross talk between the immune system and osteoclasts in osteoclastogenesis. Osteoclasts are derived from monocyte precursor cells. RANKL from.

Slides:



Advertisements
Similar presentations
Chapter 62 Chapter 62 Mechanisms of Bone Destruction in Myeloma Copyright © 2013 Elsevier Inc. All rights reserved.
Advertisements

M1 – Immunology CYTOKINES AND CHEMOKINES March 26, 2009 Ronald B
Cytokines Non-antibody proteins acting as mediators between cells, termed: Monokines – mononuclear phagocytes Lymphokines – activated T cells, especially.
Abbreviations: COX-2, cyclooxygenase-2; Gpx3, glutathione peroxidase 3; IGF, insulin-like growth factor; IKK, I kappa B kinase; IκBα, inhibitor of kappa.
Autoimmune theory of the pathogenesis of multiple sclerosis (MS)
Relapsed/Refractory Multiple Myeloma: Defining Refractory Disease and Identifying Strategies to Overcome Resistance  David S. Siegel  Seminars in Hematology 
The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation.
Myeloma cell interaction with extracellular matrix (ECM) and accessory cells in the marrow. Myeloma cells require support from bone marrow stromal cells.
What are the effector pathways, transcriptional regulators and activators of synovial tissue macrophages in healthy donors and in patients with RA in remission?
Other Cells of Immune System
From: monocytes, macrophages and DCs
Figure 1 Radiation-induced effects on tumour cells
Immunologic pathomechanism of Hodgkin's lymphoma
Figure 3 Altered adaptive immune functions after sepsis
Chlamydophila pneumoniae
Figure 2 Main functions of IL-1
Oncology Meets Immunology: The Cancer-Immunity Cycle
Figure 3 The T-cell cytokine tree in IBD
Emmanuel Contassot, Lars E. French 
Germaine Wong, Jeremy R. Chapman, Jonathan C. Craig 
Immunologic pathomechanism of Hodgkin's lymphoma
The Th17 immune response in renal inflammation
Markers of cancer cell and lymphocytes in inflammatory infiltration around a tumour as potential markers of immunomodulatory treatment response. Markers.
by Edward S. Morris, Kelli P. A. MacDonald, and Geoffrey R. Hill
It Takes Two to Tango Immunity
Malaria Vaccine Design: Immunological Considerations
Fig. 2. Functions of NOD-like receptors
Stefan H.E. Kaufmann, Shreemanta K. Parida  Cell Host & Microbe 
R. Balfour Sartor, MD  Clinical Gastroenterology and Hepatology 
T –HELPER CELL AMMAR HADI
Georges Makhoul, MD, MS, Ray C.J. Chiu, MD, PhD, Renzo Cecere, MD, MS 
Unraveling the Pros and Cons of Interferon-γ Gene Regulation
Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC
Immunotherapy of aspergillosis
Interleukin-17 Kick-Starts T Helper 1 Cell Differentiation
Pro-endometriotic niche in endometriosis
Figure 2 APCs from laquinimod-treated mice inhibit differentiation of Tfh cells APCs from laquinimod-treated mice inhibit differentiation of Tfh cells.
Emmanuel Contassot, Lars E. French 
Nat. Rev. Rheumatol. doi: /nrrheum
Under osteoporotic conditions, several proinflammatory cytokines ...
Volume 33, Issue 4, Pages (October 2010)
Cell biology of the osteoclast
Osteopontin in diabetic nephropathy: signpost or road?
Post kala-azar dermal leishmaniasis: an unresolved mystery
Jürgen C. Becker, David Schrama  Journal of Investigative Dermatology 
Nat. Rev. Urol. doi: /nrurol
Stefan H.E. Kaufmann, Shreemanta K. Parida  Cell Host & Microbe 
Pathogenesisof PsA and RA
Figure 4 Bile-acid-induced TGR5 signalling pathways in macrophages
Nat. Rev. Rheumatol. doi: /nrrheum
Figure 3 Underlying mechanisms of TREG cells in atherosclerosis
Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide
Cell-mediated immunity Regulation of the immune response
V.A.C.M. Koeken, A.J. Verrall, M.G. Netea, P.C. Hill, R. van Crevel 
Frank O. Nestle, Curdin Conrad  Journal of Investigative Dermatology 
Benjamin Lockshin, MD, Yevgeniy Balagula, MD, Joseph F
Nat. Rev. Endocrinol. doi: /nrendo
Figure 1 The role of macrophages in RA
Sotirios Tsiodras, MD, MSc, ScD, George Samonis, MD, Dimitrios T
Regulatory role of iNKT cells in T1D in humans and mice
Cross-regulation of Signaling Pathways by Interferon-γ: Implications for Immune Responses and Autoimmune Diseases  Xiaoyu Hu, Lionel B. Ivashkiv  Immunity 
Alternatively activated macrophages as therapeutic agents for kidney disease: in vivo stability is a key factor  Senthilkumar Alagesan, Matthew D. Griffin 
Plasmacytoid Dendritic Cells in Melanoma: Can We Revert Bad into Good?
Influence of the tumor microenvironment on FL
Wolbachia-induced responses of specific cell types.
TGF-β1 down-regulates induced expression of both class II MHC and B7-1 on primary murine renal tubular epithelial cells  Nazifa Banu, Catherine M. Meyers 
Fig. 2. Effect of activated vitamin D on immune cells
Post kala-azar dermal leishmaniasis: an unresolved mystery
Regulation of osteoclastogenesis by receptor activator of NF-κB ligand (RANKL) and osteoprotegerin (OPG): Colony-stimulating factor 1 (CSF-1) normally.
Differential pathway regulation in advanced idiopathic pulmonary fibrosis (IPF) lung. a) Metacore analyses of pathway enrichment in IPF versus control.
Presentation transcript:

Figure 1. Cross talk between the immune system and osteoclasts in osteoclastogenesis. Osteoclasts are derived from monocyte precursor cells. RANKL from B cell and IL-17 from Th17 cell induces osteoclastogenesis. IL-10 from Treg, IFN-γ from Th1, and IL-4 from Th2 inhibits osteoclastogenesis. I: major histocompatibility complex (MHC) class I, II: MHC class II, IFN: interferon, IL: interleukin, OPG: osteoprotegerin, RANKL: receptor activator of nuclear factor-kappa B ligand, Th1/2/17: T helper cells type 1/2/17, TGF: transforming growth factor, TNF: tumor necrosis factor, Treg: regulatory T cell. Figure 1. Cross talk between the immune system and osteoclasts in osteoclastogenesis. Osteoclasts are derived from monocyte precursor cells. RANKL from B cell and IL-17 from Th17 cell induces osteoclastogenesis. IL-10 from Treg, IFN-γ from Th1, and IL-4 from Th2 inhibits osteoclastogenesis. I: major histocompatibility complex (MHC) class I, II: MHC class II, IFN: interferon. . . J Rheum Dis. 2016 Jun;23(3):141-147. http://dx.doi.org/10.4078/jrd.2016.23.3.141

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.